Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Next Previous
Trial Profile

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vimseltinib (Primary)
  • Indications Giant cell tumour of tendon sheath; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Deciphera Pharmaceuticals

Most Recent Events

  • 06 Feb 2024 According to Deciphera Pharmaceuticals media release, the company expects to initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of chronic graft versus host disease (cGVHD) in the fourth quarter of 2024.
  • 08 Jan 2024 According to a Deciphera Pharmaceuticals media release, data from this trial will be presented in the second half of 2024.
  • 30 Oct 2023 According to a Deciphera Pharmaceuticals media release, updated results from this study will be presented at the Connective Tissue Oncology Society 2023 Annual Meeting in Dublin, Ireland on November 1-4, 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top